Drugs / AlloVax
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01995227 | Dec 2013 → Feb 2018 | hepatocellular carcinoma | Mirror Biologics, Inc. | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02624999 | Dec 2016 | head and neck squamous cell carcinoma | Mirror Biologics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02409524 | Jul 2016 → Jun 2017 | adult hepatocellular carcinoma | Mirror Biologics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01998542 | Jan 2016 → Jun 2017 | head and neck squamous cell carcinoma | Mirror Biologics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AlloVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02409524 ↗ |
| Modality | Vaccine | “personalized anti-cancer vaccine AlloVax(TM)” NCT01995227 ↗ |